Leerink Partners analyst Michael Cherny maintained a Hold rating on DENTSPLY SIRONA on September 9 and set a price target of $14.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Cherny’s rating is based on several considerations surrounding DENTSPLY SIRONA’s strategic decisions and market performance. One key factor is the company’s decision to retain the Wellspect business, which, despite its growth and financial profile, does not align closely with the core dental market. This decision suggests limited opportunities for investor value creation, as it marks the second time the company has evaluated and retained Wellspect without pursuing alternatives that might enhance shareholder value.
Additionally, while Wellspect has shown consistent growth, the broader potential for XRAY shares appears to hinge more on the company’s ability to revitalize its main dental business under new management. The retention of Wellspect, therefore, does not significantly alter the company’s growth trajectory or market position, leading to the Hold rating as the upside potential remains tied to improvements in the core dental segment rather than the retained business.
Cherny covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Doximity, and Align Tech. According to TipRanks, Cherny has an average return of 4.1% and a 53.44% success rate on recommended stocks.
In another report released on September 8, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.00 price target.